Results 141 to 150 of about 68,914 (294)

Early and late outcomes after heart transplantation in a low-volume transplant centre [PDF]

, 2012
Early (one year) and late (15 year) outcomes after heart transplantation in Malta were evaluated by means of a retrospective analysis of mortality and morbidity, derived from the transplant database.
Manche, Alexander
core  

Hyperlipidaemia and post‐heparin lipase activities in renal transplant recipients treated with sirolimus or cyclosporin A [PDF]

, 2000
Ziad A. Massy, J.‐P. De Bandt, Emmanuel Morélon, Marc Thévenin, Bernard Lacour, Henri Kreis   +5 more
openalex   +1 more source

Top advances of the year: Developments of immunotherapy in cutaneous squamous cell carcinoma, 2023–2024

Cancer, Volume 131, Issue 11, 1 June 2025.
Abstract Antibodies against PD‐1 (PD1i), such as cemiplimab and pembrolizumab, have demonstrated significant efficacy in advanced, unresectable cutaneous squamous cell carcinoma (cSCC). These agents elicit durable responses in approximately 45% of patients, contributing to improved aesthetic, functional, and survival outcomes in a subset of individuals
Mateus Trinconi Cunha, Neil Wallace, Sandro Porceddu, Renata Ferrarotto   +3 more
wiley   +1 more source

A RANDOMIZED TRIAL OF SIROLIMUS, CYCLOSPORINE AND PREDNISONE VS CYCLOSPORINE - PREDNISONE ALONE IN RECIPIENTS OF MISMATCHED FIRST KIDNEY GRAFTS: RESULTS AT ONE YEAR

, 1999
A. S. Macdonald
openalex   +1 more source

Preventative treatment of tuberous sclerosis complex with sirolimus: Phase I safety and efficacy results

Annals of the Child Neurology Society
Objective Tuberous sclerosis complex (TSC) results from overactivity of the mechanistic target of rapamycin (mTOR). Sirolimus and everolimus are mTOR inhibitors that treat most facets of TSC but are understudied in infants.
Jamie K. Capal, David M. Ritter, David Neal Franz, Molly Griffith, Kristn Currans, Bridget Kent, E. Martina Bebin, Hope Northrup, Mary Kay Koenig, Tomoyuki Mizuno, Alexander A. Vinks, Stephanie L. Galandi, Wujuan Zhang, Kenneth D.R. Setchell, Kelly M. Kremer, Carlos M. Prada, Hansel M. Greiner, Katherine Holland‐Bouley, Paul S. Horn, Darcy A. Krueger   +19 more
doaj   +1 more source

SIROLIMUS (RAPAMYCIN)-BASED THERAPY IN HUMAN RENAL TRANSPLANTATION

, 1999
Carl G. Groth, Lars Bäckman, José-Maria Morales, Roy Calne, Henri Kreis, Philippe Lang, Jean-Louis Touraine, Kerstin Claesson, Josep M. Campistol, D. Durand, Lars Wramner, C Brattström, Bernard Charpentier   +12 more
openalex   +1 more source

Autoimmune Complications of Lymphoproliferative Diseases

Hematological Oncology, Volume 43, Issue S2, June 2025.
ABSTRACT Peripheral autoimmune cytopenias may complicate a fraction of lymphoproliferative disorders (LPD), particularly chronic lymphocytic leukemia, non‐Hodgkin B‐cell lymphomas, angioimmunoblastic T‐cell lymphoma and large granular lymphocytic leukemia.
Wilma Barcellini, Bruno Fattizzo
wiley   +1 more source

TRIGLYCERIDE (TG) ELEVATIONS IN RENAL TRANSPLANT RECIPIENTS TREATED WITH SIROLIMUS (RAPAMYCIN, RAPA) ADDED TO A CYCLOSPORINE (CsA)/PREDNISONE (PRED) REGIMEN

, 1999
B D Kahan, Jonathan S. Jaffe
openalex   +1 more source

Targeting the Enhanced Sensitivity of Radiotherapy in Cancer: Mechanisms, Applications, and Challenges

MedComm, Volume 6, Issue 6, June 2025.
In this review, we first introduced the current application scenarios for radiotherapy in tumor treatment, the molecular mechanisms underlying anticancer effects of radiotherapy in treatment of cancer, and the side‐effects of radiotherapy. Second, we pay attention to discuss the main types of radiosensitizers and their latest applications and ...
Yuanyuan Zhao, Fangqin Tan, Jiajia Zhao, Shuchang Zhou, Yao Luo, Chen Gong   +5 more
wiley   +1 more source

ONE-YEAR OUTCOME AFTER STEROID WITHDRAWAL FROM A SIROLIMUS-CYCLOSPORINE-PREDNISONE REGIMEN IN CADAVER- AND LIVING-DONOR RECIPIENTS.

, 1998
B D Kahan, Mark D. Pescovitz, Gcw Chan, J Neylan, Bruce A. Julian, S. M. Katz, C.T. Van Buren   +6 more
openalex   +1 more source